Literature DB >> 23990461

Direct comparison of mice null for liver or intestinal fatty acid-binding proteins reveals highly divergent phenotypic responses to high fat feeding.

Angela M Gajda1, Yin Xiu Zhou, Luis B Agellon, Susan K Fried, Sarala Kodukula, Walter Fortson, Khamoshi Patel, Judith Storch.   

Abstract

The enterocyte expresses two fatty acid-binding proteins (FABP), intestinal FABP (IFABP; FABP2) and liver FABP (LFABP; FABP1). LFABP is also expressed in liver. Despite ligand transport and binding differences, it has remained uncertain whether these intestinally coexpressed proteins, which both bind long chain fatty acids (FA), are functionally distinct. Here, we directly compared IFABP(-/-) and LFABP(-/-) mice fed high fat diets containing long chain saturated or unsaturated fatty acids, reasoning that providing an abundance of dietary lipid would reveal unique functional properties. The results showed that mucosal lipid metabolism was indeed differentially modified, with significant decreases in FA incorporation into triacylglycerol (TG) relative to phospholipid (PL) in IFABP(-/-) mice, whereas LFABP(-/-) mice had reduced monoacylglycerol incorporation in TG relative to PL, as well as reduced FA oxidation. Interestingly, striking differences were found in whole body energy homeostasis; LFABP(-/-) mice fed high fat diets became obese relative to WT, whereas IFABP(-/-) mice displayed an opposite, lean phenotype. Fuel utilization followed adiposity, with LFABP(-/-) mice preferentially utilizing lipids, and IFABP(-/-) mice preferentially metabolizing carbohydrate for energy production. Changes in body weight and fat may arise, in part, from altered food intake; mucosal levels of the endocannabinoids 2-arachidonoylglycerol and arachidonoylethanolamine were elevated in LFABP(-/-), perhaps contributing to increased energy intake. This direct comparison provides evidence that LFABP and IFABP have distinct roles in intestinal lipid metabolism; differential intracellular functions in intestine and in liver, for LFABP(-/-) mice, result in divergent downstream effects at the systemic level.

Entities:  

Keywords:  Fatty Acid; Fatty Acid-binding Protein; Intestine; Lipid Metabolism; Monoacylglycerol

Mesh:

Substances:

Year:  2013        PMID: 23990461      PMCID: PMC3798498          DOI: 10.1074/jbc.M113.501676

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  80 in total

1.  Visualization of sex-dimorphic changes in the intestinal transcriptome of Fabp2 gene-ablated mice.

Authors:  Michael G Sugiyama; Luc Hobson; Al B Agellon; Luis B Agellon
Journal:  J Nutrigenet Nutrigenomics       Date:  2012-05-11

2.  Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat.

Authors:  S J Smith; S Cases; D R Jensen; H C Chen; E Sande; B Tow; D A Sanan; J Raber; R H Eckel; R V Farese
Journal:  Nat Genet       Date:  2000-05       Impact factor: 38.330

3.  The binding of fatty acids to cytoplasmic proteins: binding to Z protein in liver and other tissues of the rat.

Authors:  S Mishkin; L Stein; Z Gatmaitan; I M Arias
Journal:  Biochem Biophys Res Commun       Date:  1972-06-09       Impact factor: 3.575

4.  Fatty acid transfer from liver and intestinal fatty acid-binding proteins to membranes occurs by different mechanisms.

Authors:  K T Hsu; J Storch
Journal:  J Biol Chem       Date:  1996-06-07       Impact factor: 5.157

5.  Decreased body weight and hepatic steatosis with altered fatty acid ethanolamide metabolism in aged L-Fabp -/- mice.

Authors:  Elizabeth P Newberry; Susan M Kennedy; Yan Xie; Jianyang Luo; Rosanne M Crooke; Mark J Graham; Jin Fu; Daniele Piomelli; Nicholas O Davidson
Journal:  J Lipid Res       Date:  2012-02-10       Impact factor: 5.922

6.  Metabolism of apical versus basolateral sn-2-monoacylglycerol and fatty acids in rodent small intestine.

Authors:  Judith Storch; Yin Xiu Zhou; William S Lagakos
Journal:  J Lipid Res       Date:  2008-04-17       Impact factor: 5.922

7.  Increased susceptibility to diet-induced gallstones in liver fatty acid binding protein knockout mice.

Authors:  Yan Xie; Elizabeth P Newberry; Susan M Kennedy; Jianyang Luo; Nicholas O Davidson
Journal:  J Lipid Res       Date:  2009-01-09       Impact factor: 5.922

Review 8.  The emerging functions and mechanisms of mammalian fatty acid-binding proteins.

Authors:  Judith Storch; Betina Corsico
Journal:  Annu Rev Nutr       Date:  2008       Impact factor: 11.848

9.  Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin.

Authors:  Galina Burdyga; Simon Lal; Andrea Varro; Rod Dimaline; David G Thompson; Graham J Dockray
Journal:  J Neurosci       Date:  2004-03-17       Impact factor: 6.167

10.  Intestinal mucosal triacylglycerol accumulation secondary to decreased lipid secretion in obese and high fat fed mice.

Authors:  John D Douglass; Nashmia Malik; Su-Hyoun Chon; Kevin Wells; Yin Xiu Zhou; Andrew S Choi; Laurie B Joseph; Judith Storch
Journal:  Front Physiol       Date:  2012-02-24       Impact factor: 4.566

View more
  23 in total

1.  Association of L-FABP T94A and MTP I128T polymorphisms with hyperlipidemia in Chinese subjects.

Authors:  Yingying Tian; Hui Li; Shanbo Wang; Jin Yan; Zhiheng Chen; Zhenyu Li; Han Feng; Honghao Zhou; Dongsheng Ouyang
Journal:  Lipids       Date:  2015-02-07       Impact factor: 1.880

Review 2.  Acyl-CoA metabolism and partitioning.

Authors:  Trisha J Grevengoed; Eric L Klett; Rosalind A Coleman
Journal:  Annu Rev Nutr       Date:  2014-04-10       Impact factor: 11.848

3.  FABP1 knockdown in human enterocytes impairs proliferation and alters lipid metabolism.

Authors:  Luciana Rodriguez Sawicki; Natalia María Bottasso Arias; Natalia Scaglia; Lisandro Jorge Falomir Lockhart; Gisela Raquel Franchini; Judith Storch; Betina Córsico
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2017-09-13       Impact factor: 4.698

Review 4.  Intestinal triacylglycerol synthesis in fat absorption and systemic energy metabolism.

Authors:  Chi-Liang Eric Yen; David W Nelson; Mei-I Yen
Journal:  J Lipid Res       Date:  2014-09-17       Impact factor: 5.922

Review 5.  Enterocyte fatty acid-binding proteins (FABPs): different functions of liver and intestinal FABPs in the intestine.

Authors:  Angela M Gajda; Judith Storch
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2014-10-14       Impact factor: 4.006

6.  Muscle metabolic reprogramming underlies the resistance of liver fatty acid-binding protein (LFABP)-null mice to high-fat feeding-induced decline in exercise capacity.

Authors:  Heli Xu; Angela M Gajda; Yin Xiu Zhou; Cristina Panetta; Zoe Sifnakis; Anam Fatima; Gregory C Henderson; Judith Storch
Journal:  J Biol Chem       Date:  2019-08-26       Impact factor: 5.157

7.  Fabp1 gene ablation inhibits high-fat diet-induced increase in brain endocannabinoids.

Authors:  Gregory G Martin; Danilo Landrock; Sarah Chung; Lawrence J Dangott; Drew R Seeger; Eric J Murphy; Mikhail Y Golovko; Ann B Kier; Friedhelm Schroeder
Journal:  J Neurochem       Date:  2016-11-29       Impact factor: 5.372

8.  Two fatty acid-binding proteins expressed in the intestine interact differently with endocannabinoids.

Authors:  May Poh Lai; Francine S Katz; Cédric Bernard; Judith Storch; Ruth E Stark
Journal:  Protein Sci       Date:  2020-04-28       Impact factor: 6.725

9.  Phenotypic divergence in two lines of L-Fabp-/- mice reflects substrain differences and environmental modifiers.

Authors:  Elizabeth P Newberry; Susan Kennedy; Yan Xie; Jianyang Luo; Hui Jiang; Daniel S Ory; Nicholas O Davidson
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-08-06       Impact factor: 4.052

10.  Human FABP1 T94A variant impacts fatty acid metabolism and PPAR-α activation in cultured human female hepatocytes.

Authors:  Avery L McIntosh; Huan Huang; Stephen M Storey; Kerstin K Landrock; Danilo Landrock; Anca D Petrescu; Shipra Gupta; Barbara P Atshaves; Ann B Kier; Friedhelm Schroeder
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-05-29       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.